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Implantation of the Jarvik 2000 Heart 
O. H. Frazier and Igor Gregoric 
T he axial-flow cardiac assist pump is an innovative type of iml)lautable left ventricular assist system 
(LVAS) that offers a numl)cr of advantages over con- 
ventional, pulsatilc systems. The axial-flow pure I) is 
significantly smaller than coral)arable l)ulsatile im- 
l)lantable pumps and requires no valvular mechanism. 
The constant flow of blood through the I)um I) mininfizes 
stasis anti continuously washes the inorganic surfaces, 
reducing the likelihood of device thrombosis. The con- 
stant flow also obviates the need for a coml)liance 
chamber, so venting is unnecessary. Because the axial- 
flow immp is nonl)ulsatile, trauma related to movement 
of the drivelinc (an important potential source of infec- 
tion) is significantly reduced. Whereas traditional 
LVASs necessitate a fairly extensive implant oI)eration, 
the axial-flow llUml ) is easier to implant, hcll)ing to 
minimize operative complications. As this LVAS has 
only 1 movable component, device reliability and du- 
rability are enhanced. The pump can be used to sup- 
port chihlrcn and smaller aduhs, as well as adults 
of usual size. In contrast to conventional, 1)ulsatile 
LVASs, which are intended to capture the entire left 
ventricular outi)ut and, therefore, to serve as vcntric- 
nlar rel)laccmcnt devices, the axial-flow pnm I) is best 
used as a true assist device. 
This article focuses on the Jarvik 2000 Heart (Jarvik 
Heart,  Inc., New York, NY), an electrically I)owered 
LVAS that provides continuous flow from tlle left ven- 
tricle to tlle descending thoracic aorta. This pump is 
unique in that it can be placed within the left ventricle, 
thereby avoiding the rheologic problems (negative pres- 
sure stasis) associated with an inflow conduit. The Jar- 
vik 2000 system, which has been described elsewhere 
FIG I. The Jarvik 2000 left ventricular assist system. 
(see Reference section) 1-7 consists of a blood pump, 
Dacron outflow graft (DuPont, Wilmington, DE), per- 
cutaneous power cable, punq)-spccd controller, and 
direct-current power supply (Fig I). Initial clinical 
studies have shown that the Jarvik 2000 can safely and 
satisfactorily support patients with scvcrc heart failure 
who are awaiting transplantation. Wc describe the sur- 
gical technique that we use for implanting this LVAS. 
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SURGICAL TECHNIQUE 
Preparat ion  o f  tile Pmnp 
Before implanting tile Jarvik 2000 pump, the opera- 
tor should careful ly inspect the device to verify that 
tile bearings are intact and that none of the cable 
connections are cracked or broken. To confirm that the 
pump Ires not been danlaged uring slfipment, it should 
be tested in a pitcher of saline solution. 
The driveline is then prepared for tlmneling. The 
end of a 40-F Argyle chest ube is cut at an angle and is 
slit for approximately 6 cm. Tllis will allow the operator 
to place the driveline inside tile chest tulle and thereby 
protect ile connector during the tunneling procedure. 
Tile chest ube is secured to the driveline with unlbilical 
tape. 
A finger cut from a sterile glove may be used to 
cover the pump inflow cannula and prevent contanl- 
ination during passage. The pump is resubmerged in
saline sohttion, wllere it is kept until the time of 
inlplantation. 
]l Tile Jarvik 2000 i)uml I is hnplantcd throu~l a left thora- 
cotomy. Tile llatient is placed in the right lateral decul)itus posi- 
tion, at an an#e of approxSmately 45 degrees, wifll file hills 
rotated to allow exposure of the left femorM artery for cardio- 
puhnonal T bypass cammlafion. A left thoracotomy incision is 
made throu#l the 5th or 6th intercostal space, allo~Jng ex]~osure 
to tile apex of the left ventricle and tile descending thoracic aorta. 
Tile pericardium is incised lon~tudinally, avoiding injury to 
tile phrenic nerve. The descending aorta is exposed. Division 
of the inferior pulmonary ligament may facilitate xposure. To 
improve tile snr~cal view, tile left hmg may be collapsed if this 
does not result in cardiovascular compronfise. Anticoa~da- 
tion is then achieved with intravenous heparin (1 mg/kg). 
2 Once tile descending aorta has been exposed, the 
12-ram Hemaslliehl outflow graft (Boston Scientific, Natick, 
MA) is transected. With the aid of a partial-occlusion 
clamp, tile free portion of the graft is anastomosed to tile 
mid-descending aorta: Tile aorta is incised longitudinally, 
and tile end-to-side anastomosis is completed ~ith a run- 
ning 4-0 polyproI)ylene suture. The outflow graft is then 
clamped, the aortic clamp is released, and pledgeted sutures 
are used, if necessary, to obtain hemostasis. All additional 
close of heparin (2 mg/kg) is then administered, and femoral 
cannulation is completed. 
I 
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~]~ The driveline is tunneled through the dia- 
ldwagm, under the left costal margin, and is pulled 
through the subcutaneous tissue of the abdominal 
wall. For this purpose, a 10-mm incision is made in 
tile right upper abdominal quadrant, in the mid- 
clavicular line, 5 cm below the costal margin. The 
subcutaneous tunnel is created with a tunneler, 
and tile chest tube-driveline is lmlled through. The 
Jarvik l)ump is placed in position, and the length of 
the driveline needed to exit the chest wall is esti- 
mated. A strain-relief loop must be created in the 
thoracic cavity to allow for movelnent of the ab- 
dominal calde as the heart contracts. Once the 
drivcline has been tunneled, the abdominal cable 
can be connected in preparation for starting the 
lnnnp. 
4 Tile next step involves attaching tile Silastic sewing ring to tile apex of tile heart. This is done 
with an interrupted, pledgeted 2-0 Ethibond suture (Ethicon, Somerville, N J). The sewing ring 
is positioned about 2 cm lateral to tile left anterior descending artery, on tile apex of tile heart. 
To allow proper positioning of the Jarvik lmmp on insertion, the bevel of the sewing ring must 
be oriented toward the aortic valve position. During attachment, he shape of the sewing ring is 
maintained by a hard inner plastic ring, which shouhl be kept in place until the pmnp is ready 
for insertion. 
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5 After the sewing ring has been secured, femoral cannnlation for eardiopulmonary bypass is 
completed, and the patient is placed in tile Trendelenburg position. Transesophageal ehocar- 
diography should be available for intraoperative cardiac assessment and to aid in the de-aeration 
process. Once cardiopuhnonary b pass has begun, the heart is fibrillated with an external 
elfieardial fibrillator. A scalpel is then Used to make an incision through the myoeardinm inside 
the sewing ring. The myoeardium is cored with all obturator coring knife. 
6 Tile coring knife is inserted into tile ventricular cavity and is then twisted while being lmllcd 
outward. 
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7 After the full-thickness myocardial plug has been removed, the pum I) is inserted into the 
ventricle. It is secured through the sewing ring with 2 umbilical tapes. Before the tapes are 
tightened, tile pump is rotated to ensure proper positioning of tile electrical wires anti outflow 
graft. Tile heart is defibrillated, and wcaning from cardiopulmonary b pass is initiated. 
~]~ Once tile correct length and orientation of tile outflow graft have been obtained, the 2 grafts 
are anastomosed nd-to-end with 5-0 polypropylene sutures. The graft is de-aired with a 19-gauge 
needle, and tile pump is then started at 8,000 revolutions per minute (tile minimal speed setting). 
Cardiopulmonary bypass is discontinued, tIemodynamic assessment is performed with trans- 
esophageal echocardiograplly, a pulmouary artery catheter, an arterial pressure line, and a 16-mm 
uhrasonic flow probe on tile pmnp's outflow graft. This flow probe is removed before tile 
thoracotomy incision is closed. Once proper functioning of tile Jarvik 2000 heart has been 
confirmed, the cannulation sites are closed routinely. Thoracic hemostasis i  obtained, chest 
tubes are inserted, and the tlloracotomy incision is closed in tile normal fashion. The driveline is 
secured with a 0-0 polypropylene sutur e. 
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Postoperat ive  Management  
During the early postoperative period, hemodynamic 
fimction is assessed with an arterial pressure line, a 
lmhnonary artery catheter, and transthoracic cchocar- 
diography. Ideally, the immp should be maintained at 
a speed that allows the aortic valve to open with ven- 
tricular unloading. Tiffs shouhl prevent stasis and 
thrombotic omplications in the aortic root. The pres- 
ence of pulsatility alone does not ensure aortic valve 
opening. Rather, this is confirmed by observing the 
normal aortic pulse contour on the monitor. Pttmp flow 
is maintained at the lowest level comlmtible with a 
norntal cardiac index. Routine hemodynantic and echo- 
cardiographic stndies are conducted to determine the 
optimal lmntp-si~eed setting. During these tests, the 
pttmp speed is increased in 1,000-rpm increments over 
the usual operating range of 8,000 to 12,000 rpm, after 
wllich the pnmp is turned off for up to 5 minutes. 
Serial, complete 2-dimensional, M-mode, and Doppler 
eehoeardiogral~hie studies are performed at 24 ltours, 
at 1 week, at 1 month, and every 3 months thereafter. 
The Jarvik 2000 requires nfinimal routine care and 
maintenance. The lead-acid or lithium ion batteries are 
clmnged approximately every 12 hours. The pump 
speed generally remains constant but nmy be increased 
during exercise. These tasks become the patient's re- 
sponsil,ility after he or she undergoes rehabilitation 
and training. 
Comments  
Because of rapid advances in axial-flow teclmolog-y, 
immps such as the Jarvik 2000 are offering new hope to 
imtients with congestive heart failure. The imrpose of 
these devices is to augqnent left ventricular function rather 
tlmn to assume it altogether. Wlfile the Immp is in place, 
the constant blood flow through the pump ensures con- 
tinuous left ventrieular unloadhag. The role of anticoa~l- 
lant therapy in Jarvik 2000 reeilfients i not yet clear. Tile 
puml)'S reduced thrombogenieity has been ga'atifying. It 
may be related to the ldtra-smooth titalfium surface, con- 
tinuous blood flow, and nfinimal foreigm-surface area. 
The Jarvik 2000 was designed to be reliable, easy to 
implant, and simple to operate, and we believe that 
these goals lmve been met. Implantation is less exten- 
sive and less time-consuming than with other implant- 
aide LVASs, so the rate of surgical complications, in- 
eluding serious hemorrhages and implant-related infec- 
tions, is reduced. Patients and their eare~vers find tile 
system easy to operate. In our series of 22 patients, 
there have been no technical problems with system 
components. As experience with axial-flow pumps con- 
tinnes to accumulate, these devices can be expected to 
salvage an increasing number of terminally ill patients. 
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